2019 Press Releases

Keyword Search
 
2019 | 2018 | 2017 | 2016 | 2015 | 2014
DateTitle 
01/17/19Aerpio Pharmaceuticals Announces Completion of Patient Dosing in TIME-2b Study of AKB-9778 in Diabetic Retinopathy
CINCINNATI--(BUSINESS WIRE)--Jan. 17, 2019-- Aerpio Pharmaceuticals, Inc. (Nasdaq: ARPO), a biopharmaceutical company focused on developing compounds that activate Tie2 to treat ocular diseases and diabetic complications, today announced the completion of patient dosing in the Company’s TIME-2b study, a Phase 2b clinical trial designed to assess the efficacy and safety of Aerpio’s lead candidate, AKB-9778, for patients with moderate to severe non-prolife... 
Printer Friendly Version